Why Is VERADERMICS INC (MANE) Stock Down Today?

MANE stock closed down 8.12% at $113.66 on Thursday, reversing earlier gains amid mixed investor reaction to recent clinical data. The stock opened at $123.69 but fell sharply throughout the session, hitting a low of $112.27 before closing near the bottom of the range. The move reflects a shift in sentiment following news of positive trial results, though the stock has not maintained the upward momentum seen earlier in the day.

What Happened

Veradermics announced that its Phase 2 trial for VDPHL01 showed an increase in hair count among female subjects as early as the second month of treatment. The results were reported by multiple outlets and cited as a key driver of an earlier 9% intraday gain. However, by the end of the session, the stock had given back those gains and more, closing at a level below the morning high. The rapid reversal suggests some profit-taking or skepticism about the sustainability of the momentum. The company’s shares have been volatile in recent months, with a 52-week range of $32.00 to $131.24.

What The Data Shows

The stock traded at 0.7 times its 3-month average volume, with 0.4 million shares changing hands by the close. The intraday high of $125.17 was reached shortly after the open, but the stock declined steadily for much of the session. MANE has a market capitalization of $4.6 billion and remains unprofitable, with an EPS TTM of -15.84. The stock’s recent performance reflects the high expectations and volatility typical of a biotech firm in the development stage.

What To Watch

Investors should monitor the topline results of Veradermics’ Phase 2/3 Study 306, expected in the first half of 2027. These results could provide further clarity on the drug’s potential and influence the stock’s trajectory. Coverage breadth and analyst commentary will also be important to watch in the coming weeks.